Japan’s Regenerative Medicine Enters the Stage of Clinical Implementation: iPS Approvals, Conditional and Time-Limited Approval, and the Boundaries of Patient Expectations
Reading Japan’s iPS-based regenerative medicine through Amchepry, Heartseed HS-005 and the PMDA conditional, time-limited approval pathway — why it draws attention, and why the results still need careful interpretation.